vs

Side-by-side financial comparison of iQSTEL Inc (IQST) and MEDIFAST INC (MED). Click either name above to swap in a different company.

iQSTEL Inc is the larger business by last-quarter revenue ($84.2M vs $75.1M, roughly 1.1× MEDIFAST INC). On growth, iQSTEL Inc posted the faster year-over-year revenue change (-14.9% vs -36.9%). iQSTEL Inc produced more free cash flow last quarter ($-1.2M vs $-6.6M). Over the past eight quarters, iQSTEL Inc's revenue compounded faster (28.0% CAGR vs -34.4%).

iQSTEL Inc is a technology holding company operating three core segments: telecommunications, Internet of Things (IoT), and fintech. It offers connectivity services, smart IoT monitoring solutions, and digital financial tools, mainly serving small and medium-sized enterprises and retail customers in North and South American markets.

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

IQST vs MED — Head-to-Head

Bigger by revenue
IQST
IQST
1.1× larger
IQST
$84.2M
$75.1M
MED
Growing faster (revenue YoY)
IQST
IQST
+22.0% gap
IQST
-14.9%
-36.9%
MED
More free cash flow
IQST
IQST
$5.4M more FCF
IQST
$-1.2M
$-6.6M
MED
Faster 2-yr revenue CAGR
IQST
IQST
Annualised
IQST
28.0%
-34.4%
MED

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IQST
IQST
MED
MED
Revenue
$84.2M
$75.1M
Net Profit
$-2.7M
Gross Margin
3.5%
69.4%
Operating Margin
-2.9%
-10.4%
Net Margin
-3.2%
Revenue YoY
-14.9%
-36.9%
Net Profit YoY
-44.5%
EPS (diluted)
$-0.92
$-1.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IQST
IQST
MED
MED
Q4 25
$84.2M
$75.1M
Q3 25
$102.9M
$89.4M
Q2 25
$72.2M
$105.6M
Q1 25
$57.6M
$115.7M
Q4 24
$98.9M
$119.0M
Q3 24
$54.2M
$140.2M
Q2 24
$78.6M
$168.6M
Q1 24
$51.4M
$174.7M
Net Profit
IQST
IQST
MED
MED
Q4 25
$-2.7M
Q3 25
$-2.3M
$-2.3M
Q2 25
$-2.3M
$2.5M
Q1 25
$-1.1M
$-772.0K
Q4 24
$-1.9M
Q3 24
$-773.0K
$1.1M
Q2 24
$-2.0M
$-8.2M
Q1 24
$-580.2K
$8.3M
Gross Margin
IQST
IQST
MED
MED
Q4 25
3.5%
69.4%
Q3 25
2.7%
69.5%
Q2 25
2.6%
72.6%
Q1 25
3.4%
72.8%
Q4 24
2.7%
74.1%
Q3 24
3.7%
75.4%
Q2 24
2.8%
73.2%
Q1 24
2.7%
72.8%
Operating Margin
IQST
IQST
MED
MED
Q4 25
-2.9%
-10.4%
Q3 25
-0.5%
-4.6%
Q2 25
-0.9%
-1.0%
Q1 25
-1.0%
-1.1%
Q4 24
-0.3%
0.6%
Q3 24
-0.1%
1.5%
Q2 24
-0.4%
-4.7%
Q1 24
-0.4%
4.5%
Net Margin
IQST
IQST
MED
MED
Q4 25
-3.2%
Q3 25
-2.3%
-2.5%
Q2 25
-3.3%
2.3%
Q1 25
-2.0%
-0.7%
Q4 24
-1.9%
Q3 24
-1.4%
0.8%
Q2 24
-2.5%
-4.8%
Q1 24
-1.1%
4.8%
EPS (diluted)
IQST
IQST
MED
MED
Q4 25
$-0.92
$-1.64
Q3 25
$-0.68
$-0.21
Q2 25
$-0.82
$0.22
Q1 25
$-0.44
$-0.07
Q4 24
$-1.19
$0.08
Q3 24
$-0.40
$0.10
Q2 24
$-0.90
$-0.75
Q1 24
$-0.37
$0.76

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IQST
IQST
MED
MED
Cash + ST InvestmentsLiquidity on hand
$2.2M
$167.3M
Total DebtLower is stronger
$4.1M
Stockholders' EquityBook value
$16.3M
$198.9M
Total Assets
$51.1M
$248.0M
Debt / EquityLower = less leverage
0.25×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IQST
IQST
MED
MED
Q4 25
$2.2M
$167.3M
Q3 25
$2.3M
$173.5M
Q2 25
$2.0M
$162.7M
Q1 25
$1.1M
$164.6M
Q4 24
$2.5M
$162.3M
Q3 24
$2.1M
$170.0M
Q2 24
$797.2K
$163.5M
Q1 24
$2.7M
$156.4M
Total Debt
IQST
IQST
MED
MED
Q4 25
$4.1M
Q3 25
$2.7M
Q2 25
$4.5M
Q1 25
$3.5M
Q4 24
$2.5M
Q3 24
$3.2M
Q2 24
$2.5M
Q1 24
$194.0K
Stockholders' Equity
IQST
IQST
MED
MED
Q4 25
$16.3M
$198.9M
Q3 25
$17.9M
$214.7M
Q2 25
$14.3M
$216.0M
Q1 25
$11.6M
$211.0M
Q4 24
$11.9M
$210.1M
Q3 24
$8.1M
$207.3M
Q2 24
$7.6M
$205.3M
Q1 24
$8.4M
$211.0M
Total Assets
IQST
IQST
MED
MED
Q4 25
$51.1M
$248.0M
Q3 25
$46.9M
$268.2M
Q2 25
$51.4M
$269.3M
Q1 25
$42.0M
$280.0M
Q4 24
$79.0M
$284.2M
Q3 24
$32.4M
$291.2M
Q2 24
$30.0M
$293.5M
Q1 24
$22.1M
$302.8M
Debt / Equity
IQST
IQST
MED
MED
Q4 25
0.25×
Q3 25
0.15×
Q2 25
0.31×
Q1 25
0.31×
Q4 24
0.21×
Q3 24
0.40×
Q2 24
0.34×
Q1 24
0.02×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IQST
IQST
MED
MED
Operating Cash FlowLast quarter
$-1.2M
$-5.3M
Free Cash FlowOCF − Capex
$-1.2M
$-6.6M
FCF MarginFCF / Revenue
-1.5%
-8.8%
Capex IntensityCapex / Revenue
0.0%
1.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-4.0M
$1.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IQST
IQST
MED
MED
Q4 25
$-1.2M
$-5.3M
Q3 25
$-953.0K
$12.1M
Q2 25
$257.7K
$-3.4M
Q1 25
$-1.9M
$3.4M
Q4 24
$-403.7K
$-4.9M
Q3 24
$625.0K
$9.1M
Q2 24
$-2.6M
$13.1M
Q1 24
$-536.9K
$7.3M
Free Cash Flow
IQST
IQST
MED
MED
Q4 25
$-1.2M
$-6.6M
Q3 25
$-969.2K
$10.8M
Q2 25
$211.7K
$-4.8M
Q1 25
$-2.0M
$1.9M
Q4 24
$-421.3K
$-7.2M
Q3 24
$594.5K
$7.7M
Q2 24
$-2.6M
$11.1M
Q1 24
$-608.5K
$5.4M
FCF Margin
IQST
IQST
MED
MED
Q4 25
-1.5%
-8.8%
Q3 25
-0.9%
12.0%
Q2 25
0.3%
-4.5%
Q1 25
-3.4%
1.6%
Q4 24
-0.4%
-6.1%
Q3 24
1.1%
5.5%
Q2 24
-3.4%
6.6%
Q1 24
-1.2%
3.1%
Capex Intensity
IQST
IQST
MED
MED
Q4 25
0.0%
1.8%
Q3 25
0.0%
1.5%
Q2 25
0.1%
1.3%
Q1 25
0.1%
1.3%
Q4 24
0.0%
1.9%
Q3 24
0.1%
1.0%
Q2 24
0.0%
1.1%
Q1 24
0.1%
1.1%
Cash Conversion
IQST
IQST
MED
MED
Q4 25
Q3 25
Q2 25
-1.36×
Q1 25
Q4 24
Q3 24
8.04×
Q2 24
Q1 24
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IQST
IQST

USA$53.2M63%
Other$29.9M35%
Switzerland$1.1M1%

MED
MED

Segment breakdown not available.

Related Comparisons